LOGIN  |  REGISTER
Recursion

Alpha Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

February 21, 2024 | Last Trade: US$8.00 1.79 28.82

HOLLISTER, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2023, on Monday, March 11, 2024, following the close of market.

Teknova will host a webcast and conference call on Monday, March 11, 2024, beginning at 5:30 p.m. Eastern Time. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/qqayy3wz. To receive a PIN number for dial in, participants can register for the webcast here. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova   

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. Teknova offers fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. The Company’s fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps their customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by its team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies. 

Investor Contacts 
Matt Lowell 
Chief Financial Officer 
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 831-637-1100

Media Contact 
Jennifer Henry  
Senior Vice President, Marketing 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
+1 831-313-1259

Viking Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB